ArticleESMO open2025

Outcomes with trastuzumab deruxtecan by biomarker status, line of treatment and prior receipt of sacituzumab govitecan in a large real-world database of patients with metastatic breast cancer.

P Tarantino et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.